Eli Lilly filed five new federal lawsuits on October 8, 2026, targeting sellers of unapproved retatrutide across four federal districts. The filings name American Peptides in the Western District of Louisiana, Cenexa Labs in the Southern District of Texas, MedShape Weight Loss Clinic in the District of Arizona, and LiveWell Peptides and Southlake Mhya PLLC, both in the Northern District of Texas.
The new filings bring Lilly’s total to 11 lawsuits against retatrutide sellers since August 2026. Nine cases remain active after two voluntary dismissals in September — Astra on September 2 and Aesthetic Envy, dismissed with prejudice on September 11.
The filings represent the latest step in an escalating enforcement campaign by the drugmaker against gray-market distributors of an investigational peptide that has not been approved by the FDA for any use.
What happened
According to court filings reported by Vial Audit, Lilly’s October 8 complaints allege that the five named entities sold unapproved retatrutide to consumers without regulatory authorization. The suits were filed across four federal districts spanning Louisiana, Texas, and Arizona.
Lilly previously filed six federal lawsuits in August 2026 against other retatrutide sellers. Two of those cases have since been dismissed — Astra on September 2 and Aesthetic Envy on September 11 (dismissed with prejudice) — leaving nine active cases across the combined docket.
Separately, the FDA has issued 21 warning letters to entities selling retatrutide since December 2024, according to the report.
Why it matters
Filing five new lawsuits in a single day signals a deliberate escalation in Lilly’s enforcement intensity against retatrutide distributors. The expansion from six to eleven total suits within weeks demonstrates that the company is actively pursuing new defendants beyond its initial wave of litigation.
For online peptide vendors, gray-market distributors, telehealth platforms, and compounding pharmacies handling investigational compounds, the growing docket increases legal exposure. The combination of private litigation from Lilly and FDA warning letters creates overlapping enforcement pressure on sellers of unapproved retatrutide.
Retatrutide remains an investigational compound. No version of retatrutide has been approved by the FDA for commercial sale or clinical use outside of controlled trials.
What to watch next
- Whether Lilly continues filing additional lawsuits against other named or unnamed retatrutide sellers in coming weeks.
- Outcomes of the nine active cases, including potential settlements, injunctions, or trial dates.
- Further FDA enforcement actions beyond the 21 warning letters already issued since December 2024.
- Whether telehealth platforms and compounding pharmacies adjust retatrutide offerings in response to mounting legal risk.
Sources
Industry information only. Not medical or legal advice.
